middl
east
respiratori
syndrom
coronaviru
merscov
caus
sever
diseas
human
overal
casefat
rate
effect
antivir
crucial
improv
clinic
outcom
mer
although
number
repurpos
drug
convalescentphas
plasma
antivir
peptid
neutral
antibodi
exhibit
antimerscov
activ
vitro
readili
avail
evalu
nonhuman
primat
assess
repurpos
drug
potent
vitro
antimerscov
activ
mycophenol
mofetil
mmf
lopinavirritonavir
common
marmoset
sever
diseas
resembl
mer
human
lopinavirritonavirtr
anim
better
outcom
untreat
anim
improv
clinic
mean
clinic
score
loss
untreat
anim
radiolog
minim
pulmonari
infiltr
patholog
mild
bronchointerstiti
pneumonia
find
lower
mean
viral
load
necropsi
lung
log
copiesglyceraldehyd
dehydrogenas
gapdh
p
extrapulmonari
log
copiesgapdh
p
kidney
tissu
contrast
mmftreat
anim
develop
sever
andor
fatal
diseas
higher
mean
viral
load
log
copiesgapdh
untreat
anim
mortal
rate
hour
postinocul
untreat
mmftreat
versu
lopinavirritonavirtr
lopinavirritonavir
alon
combin
evalu
clinic
trial
mmf
alon
may
worsen
mer
use
coronavirus
cov
repeatedli
cross
speci
barrier
caus
epidem
signific
socioeconom
impact
middl
east
respiratori
syndrom
coronaviru
merscov
novel
zoonot
lineag
c
discov
merscov
infect
human
mer
commonli
manifest
sever
acut
respiratori
diseas
often
complic
acut
respiratori
distress
syndrom
multiorgan
failur
clinic
deterior
death
occur
rapidli
day
earlier
mer
sever
acut
respiratori
syndrom
sar
casefat
rate
mer
highest
among
human
cov
infect
exce
effect
antivir
treatment
especi
given
earli
patient
risk
develop
sever
diseas
may
improv
clinic
outcom
mer
number
new
drug
compound
human
human
monoclon
antibodi
subunit
receptorbind
domain
antivir
peptid
target
subunit
heptad
repeat
domain
merscov
spike
glycoprotein
recent
develop
show
potent
antimerscov
activ
vitro
howev
develop
still
preclin
phase
anoth
possibl
treatment
option
mer
convalescentphas
plasma
therapi
previous
use
treat
sever
viral
respiratori
infect
includ
sar
pandem
influenza
good
clinic
virolog
respons
howev
also
readili
avail
prepar
requir
recruit
larg
number
convalesc
patient
high
serum
antibodi
titer
convalescentphas
plasma
low
serum
antibodi
titer
may
associ
immun
enhanc
could
lead
worsen
outcom
observ
vitro
anim
experi
sar
order
find
immedi
avail
treatment
mer
novel
agent
convalescentphas
plasma
therapi
becom
avail
other
appli
highthroughput
screen
identifi
exist
drug
may
repurpos
treat
patient
mer
exampl
drug
identifi
use
drug
discoveri
approach
includ
inhibitor
viru
entri
clathrinmedi
endocytosi
neurotransmitt
estrogen
receptor
kinas
signal
lipid
metabol
protein
process
dna
synthesisrepair
although
exhibit
vitro
antimerscov
activ
like
clinic
relev
either
associ
sever
advers
effect
antimerscov
halfmaxim
effect
concentr
ec
clinic
achiev
therapeut
dosag
previou
studi
identifi
mycophenol
mofetil
mmf
ribavirin
lopinavir
potenti
candid
vivo
evalu
treatment
ribavirin
shown
effect
vitro
merscovinfect
rhesu
macaqu
mild
diseas
benefit
mer
patient
obviou
studi
evalu
treatment
effect
mmf
lopinavir
merscovinfect
common
marmoset
recent
describ
nonhuman
primat
model
anim
model
best
repres
sever
human
diseas
among
exist
anim
model
mer
importantli
found
lopinavirritonavir
mmf
improv
outcom
merscovinfect
common
marmoset
find
provid
basi
futur
clinic
trial
highli
fatal
diseas
merscov
strain
kindli
provid
ron
fouchier
erasmu
medic
center
viru
propag
cell
atcc
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
unitsml
penicillin
plu
streptomycin
experi
involv
live
merscov
follow
approv
standard
oper
procedur
biosafeti
level
facil
previous
describ
tissu
cultur
infecti
dose
tcid
per
ml
determin
merscov
cell
previous
describ
experi
involv
common
marmoset
perform
previous
describ
slight
modif
approv
institut
anim
care
use
committe
briefli
healthi
male
common
marmoset
callithrix
jacchu
year
old
g
inocul
tcid
merscov
dmem
intratrach
figur
anim
randomli
assign
treatment
group
nonblind
manner
tabl
treatment
group
includ
anim
treat
sham
treatment
mmf
cellcept
roch
pharmaceut
inc
lopinavirritonavir
figur
schedul
merscov
inocul
examin
treatment
necropsi
common
marmoset
die
unexpectedli
anesthesia
hpi
like
relat
anesthesia
procedur
common
marmoset
small
fragil
abbrevi
hpi
hour
postinocul
merscov
middl
east
respiratori
syndrom
coronaviru
mmf
mycophenol
mofetil
kaletra
abbot
laboratori
recombin
betaferon
bayer
schere
pharma
germani
use
previous
describ
dosag
administ
mmf
intraperiton
subcutan
instead
intraven
oral
respect
small
vein
common
marmoset
prevent
reliabl
drug
deliveri
intraven
rout
critic
ill
mer
patient
usual
requir
parenter
treatment
lopinavirritonavir
avail
oral
prepar
initi
treatment
mmf
hour
postinocul
hpi
accord
previous
describ
treatment
model
use
merscovinfect
rhesu
macaqu
treatment
lopinavirritonavir
start
hpi
lopinavirritonavir
take
longer
achiev
peak
serum
concentr
cmax
compar
mmf
anim
observ
twice
daili
clinic
sign
score
use
previous
describ
clinic
score
system
includ
evalu
gener
appear
skin
fur
appear
discharg
oral
nasal
andor
ocular
respiratori
rate
food
consumpt
clinic
examin
studi
includ
measur
bodi
temperatur
twice
daili
bodi
weight
hpi
blood
collect
hematolog
test
hpi
necropsi
dorsalventr
later
chest
xray
cxr
perform
anesthet
anim
hpi
previous
describ
necropsi
schedul
hpi
clinic
score
previous
describ
necropsi
tissu
collect
histopatholog
immunohistochemistri
viral
load
studi
section
necropsi
tissu
stain
hematoxylin
eosin
light
microscop
examin
immunohistochem
stain
mous
antimerscov
nucleocapsid
protein
antibodi
overnight
immunofluoresc
examin
merscov
nucleocapsid
protein
express
describ
previous
rna
extract
quantit
realtim
revers
transcriptionpolymeras
chain
reaction
rtpcr
perform
necropsi
lung
kidney
liver
spleen
heart
tissu
previous
describ
three
area
sever
macroscop
lesion
obtain
necropsi
organ
viral
load
studi
briefli
total
rna
viral
rna
isol
use
trizol
life
technolog
viral
rna
mini
kit
qiagen
respect
rna
quantif
rna
revers
transcrib
complementari
dna
cdna
use
random
hexam
total
viral
transcript
detect
use
novel
coronaviru
realtim
rtpcr
assay
cdc
catalog
viral
rna
normal
messeng
rna
express
level
glyceraldehyd
dehydrogenas
gapdh
spikein
control
enteroviru
strain
use
primer
gapdh
cccaaagtagt
enteroviru
reaction
equal
amount
cdna
mix
fs
univers
sybr
green
master
rox
roch
plu
pmol
forward
revers
primer
amplif
done
condit
second
minut
cycl
realtim
pcr
detect
system
abi
statist
comparison
differ
group
perform
student
test
use
graphpad
prism
p
valu
consid
statist
signific
untreat
mmftreat
anim
develop
sever
diseas
increas
respiratori
rate
reduc
movement
loss
appetit
soon
merscov
inocul
hpi
untreat
mmftreat
anim
mean
clinic
score
figur
mean
clinic
score
peak
hpi
point
untreat
mmftreat
anim
develop
sever
dyspnea
cyanosi
bare
move
bloodstain
oral
discharg
euthan
hpi
clinic
score
exceed
euthan
anim
sever
hypothermia
necropsi
suggest
sever
diseas
shock
supplementari
figur
cxr
perform
anim
prior
necropsi
show
bilater
interstiti
infiltr
indic
extens
pneumonia
figur
remain
untreat
mmftreat
anim
surviv
continu
sever
symptom
clinic
score
figur
temperatur
baselin
level
throughout
remain
studi
period
supplementari
figur
cxr
hpi
show
interstiti
infiltr
bilater
lung
base
data
shown
hpi
untreat
mmftreat
anim
weight
loss
respect
figur
hpi
weight
loss
increas
remain
untreat
mmftreat
anim
respect
contrast
none
lopinavirritonavirtr
anim
develop
sever
symptom
howev
lopinavirritonavirtr
anim
die
unexpectedli
anesthesia
hpi
like
relat
anesthesia
procedur
common
marmoset
small
fragil
could
obtain
ethic
approv
add
anoth
anim
studi
assess
hpi
overal
mortal
rate
hpi
untreat
mmftreat
anim
lopinavir
ritonavirtr
anim
mean
clinic
score
lopinavirritonavirtr
anim
peak
hpi
gradual
improv
wherea
anim
peak
hpi
improv
figur
throughout
studi
mean
clinic
score
consist
lower
untreat
mmftreat
anim
temperatur
trend
grossli
correl
clinic
score
lowest
temperatur
occur
around
hpi
follow
normal
baselin
level
hpi
supplementari
figur
hpi
lopinavirritonavirtr
anim
weight
loss
significantli
less
untreat
anim
p
figur
hpi
weight
loss
slightli
increas
anim
also
mild
weight
loss
hpi
respect
lopinavirritonavirtr
anim
grossli
normal
cxr
appear
anim
mild
basal
interstiti
infiltr
hpi
figur
obviou
differ
mean
leukocyt
erythrocyt
platelet
count
obtain
hpi
necropsi
among
treatment
group
data
shown
howev
chang
time
point
might
overlook
small
size
anim
prevent
serial
frequent
blood
take
describ
macroscop
necropsi
lung
untreat
mmftreat
anim
show
extens
multilobar
hemorrhag
lesion
lung
firm
fluidfil
fluid
leak
figur
contrast
gross
lesion
necropsi
lung
lopinavirritonavirtr
anim
confin
lobe
figur
corrobor
mild
symptom
normal
cxr
find
lopinavirritonavirtr
anim
macroscop
lesion
lung
mildest
microscop
necropsi
lung
untreat
mmftreat
anim
show
sever
multifoc
coalesc
acut
bronchointerstiti
pneumonia
figur
pulmonari
alveoli
infiltr
larg
amount
inflammatori
cell
consist
predominantli
macrophag
neutrophil
lymphocyt
alveolar
interstitium
thicken
edema
fibrin
hemorrhag
abund
merscov
nucleocapsid
protein
express
detect
immunohistochem
stain
figur
contrast
necropsi
lung
lopinavirritonavirtr
anim
show
mild
moder
bronchointerstiti
pneumonia
confin
lobe
small
amount
inflammatori
cell
infiltr
edema
hemorrhag
figur
immunohistochem
stain
show
scarc
focal
merscov
nucleocapsid
protein
express
figur
histopatholog
chang
necropsi
extrapulmonari
tissu
treatment
group
similar
consid
nonspecif
chang
associ
hypox
damag
incident
find
common
marmoset
describ
data
shown
mean
viral
load
necropsi
lung
highest
mmftreat
anim
lowest
lopinavirritonavirtr
anim
figur
mean
viral
load
necropsi
lung
mmftreat
anim
log
copi
gapdh
higher
untreat
anim
mean
viral
load
necropsi
lung
lopinavirritonavirtr
anim
significantli
lower
untreat
anim
p
p
log
copiesgapdh
respect
mmftreat
anim
also
highest
mean
viral
load
kidney
liver
spleen
log
copiesgapdh
higher
untreat
anim
contrast
mean
viral
load
extrapulmonari
tissu
lopinavirritonavirtr
anim
consist
lower
untreat
anim
log
copiesgapdh
mean
viral
load
necropsi
kidney
tissu
lopinavirritonavirtr
anim
significantli
lower
untreat
anim
log
copiesgapdh
p
notabl
anim
actual
undetect
viral
load
necropsi
kidney
tissu
account
larg
standard
deviat
valu
appar
lack
statist
signific
differ
despit
log
copiesgapdh
reduct
compar
untreat
anim
epidem
caus
emerg
virus
de
novo
develop
novel
antimerscov
drug
lag
behind
rapid
expans
mer
epidem
recent
larg
healthcareassoci
outbreak
involv
infect
patient
close
contact
south
korea
reemphas
urgent
need
find
effect
antimerscov
treatment
drug
repurpos
especi
advantag
approach
repurpos
drug
usual
wellknown
pharmacokinet
pharmacodynam
side
effect
dose
regimen
data
would
facilit
drug
use
patient
sever
mer
often
comorbid
complic
multiorgan
dysfunct
howev
lack
suitabl
anim
model
major
obstacl
evalu
countermeasur
mer
past
year
balbc
mice
syrian
hamster
ferret
suscept
merscov
infect
merscovinfect
rhesu
macaqu
develop
mild
selflimit
diseas
intranas
administr
adenovir
vector
encod
human
dipeptidyl
receptor
use
transduc
render
balb
c
mice
suscept
merscov
infect
use
anim
model
treatment
effect
polyinosinicpolycytidyl
acid
adopt
transfer
serum
sampl
contain
antimerscov
spike
glycoprotein
antibodi
acceler
viru
clearanc
lung
demonstr
howev
infect
rel
mild
confin
respiratori
tract
mous
model
sever
pulmonari
dissemin
extrapulmonari
diseas
definit
better
still
nonhuman
primat
model
recent
common
marmoset
model
mimick
sever
dissemin
merscov
human
infect
establish
first
studi
report
use
new
nonhuman
primat
model
evalu
treatment
effect
repurpos
drug
mer
consist
find
origin
descript
common
marmoset
model
mer
untreat
anim
studi
develop
sever
diseas
merscov
inocul
compar
untreat
anim
develop
symptom
die
slightli
earlier
describ
falzarano
report
might
relat
differ
age
anim
studi
year
falzarano
studi
year
rout
viru
inocul
instead
combin
intranas
tcid
intratrach
tcid
conjunctiv
tcid
oral
tcid
inocul
total
inoculum
tcid
use
intratrach
inocul
tcid
like
result
direct
deliveri
viru
lower
respiratori
tract
faster
diseas
onset
nonetheless
overal
clinic
radiolog
patholog
virolog
find
untreat
anim
otherwis
similar
describ
previous
mimick
sever
mer
human
previous
demonstr
potent
vitro
antimerscov
activ
mmf
howev
immunosuppress
effect
mmf
far
limit
use
mer
patient
compar
ribavirin
doubt
effect
mer
patient
mmf
exhibit
much
lower
ec
mmf
ribavirin
markedli
peak
serum
level
routin
clinic
dosag
therefor
postul
less
immunosuppress
dose
mmf
could
use
treat
mer
primat
studi
show
singl
dose
mmf
long
halflif
improv
might
worsen
merscov
infect
common
marmoset
may
partial
explain
renal
transplant
recipi
mmf
still
develop
sever
fatal
mer
lopinavir
proteas
inhibitor
may
inhibit
proteas
merscov
modul
apoptosi
human
cell
kaletra
ritonavirboost
lopinavir
prepar
commonli
use
antihuman
immunodefici
viru
medic
lopinavir
exhibit
antimerscov
activ
ec
vitro
cmax
achiev
singl
mg
oral
dose
kaletra
mg
mg
ritonavir
previous
demonstr
vivo
treatment
effect
lopinavirritonavir
sar
patient
compar
control
sar
patient
receiv
ribavirin
day
patient
addit
receiv
lopinavirritonavir
mg
twice
daili
day
milder
diseas
less
diarrhea
recurr
fever
lymphopenia
nosocomi
infect
nasopharyng
viral
load
fecal
rtpcr
posit
rate
advers
outcom
patient
toler
short
cours
lopinavirritonavir
well
although
experienc
gastrointestin
upset
derang
liver
function
headach
blur
vision
anemia
asymptomat
bradycardia
mer
patient
receiv
combin
lopinavirritonavir
pegyl
interferon
ribavirin
resolut
viremia
day
treatment
present
studi
show
treatment
lopinavirritonavir
improv
clinic
radiolog
patholog
featur
merscovinfect
common
marmoset
lopinavir
ritonavirtr
anim
lowest
mean
viral
load
lung
extrapulmonari
tissu
necropsi
find
provid
support
use
lopinavirritonavir
patient
sever
mer
merscov
attenu
interferon
respons
evad
host
innat
immun
system
merscov
time
sensit
pegyl
sarscov
vitro
therefor
treatment
mer
interferon
consid
evalu
vitro
small
number
patient
cell
betaferon
exhibit
lower
ec
cmax
ratio
might
partial
explain
treatment
effect
surviv
rate
small
cohort
mer
patient
obviou
studi
show
merscovinfect
common
marmoset
treat
less
sever
diseas
lower
mean
viral
load
necropsi
lung
extrapulmonari
tissu
compar
untreat
anim
notabl
lesion
lopinavirritonavirtr
anim
confin
lobe
overal
mean
viral
load
differ
anim
untreat
anim
like
underestim
commonli
use
treat
patient
multipl
sclerosi
usual
well
toler
rare
monoclonc
gammopathi
patient
treat
may
develop
system
capillari
leak
syndrom
uncommon
side
effect
includ
hypersensit
pancreat
depress
cytopenia
cardiomyopathi
liver
thyroid
dysfunct
given
good
safeti
profil
vitro
vivo
result
use
consid
clinic
trial
mer
patient
contraind
interferon
therapi
evalu
effect
combin
treatment
drug
due
difficulti
get
approv
use
primat
nevertheless
find
nonhuman
primat
studi
encourag
conduct
clinic
trial
mer
patient
use
monotherapi
combin
treatment
repurpos
drug
vivo
antimerscov
effect
lack
drug
interact
lopinavir
ritonavir
make
attract
combin
futur
clinic
trial
contrast
still
uncertain
combin
andor
lopinavirritonavir
lower
dose
mmf
may
provid
better
viral
load
suppress
overcom
deleteri
effect
latter
drug
notabl
combin
mmf
show
synergist
effect
merscov
inhibit
vitro
combin
shown
effect
common
marmoset
may
becom
altern
treatment
option
patient
intoler
andor
lopinavirritonavir
potenti
effect
treatment
regimen
combin
ribavirin
andor
lopinavirritonavir
also
evalu
common
marmoset
model
although
use
highdos
ribavirin
limit
sever
side
effect
lowdos
ribavirin
combin
lopinavirritonavir
may
synergist
still
consid
final
shorter
median
time
interv
symptom
onset
death
mer
sar
patient
emphas
import
earli
use
antivir
combin
mer
merscov
dampen
host
innat
interferon
respons
also
effect
suppress
adapt
immun
respons
infect
lymphocyt
induct
apoptosi
via
extrins
intrins
pathway
high
percentag
peripher
blood
splenic
lymphocyt
failur
control
merscov
replic
earli
phase
diseas
may
therefor
lead
impair
adapt
immun
respons
poor
outcom
supplementari
materi
avail
journal
infecti
diseas
onlin
http
jidoxfordjournalsorg
supplementari
materi
consist
data
provid
author
publish
benefit
reader
post
materi
copyedit
content
supplementari
data
sole
respons
author
question
messag
regard
error
address
author
figur
mean
viral
load
standard
deviat
valu
differ
tissu
merscovinfect
common
marmoset
collect
time
necropsi
p
two
anim
undetect
viral
load
necropsi
kidney
tissu
account
larg
standard
deviat
valu
appar
lack
statist
signific
differ
mean
viral
load
untreat
anim
abbrevi
gapdh
glyceraldehyd
dehydrogenas
merscov
middl
east
respiratori
syndrom
coronaviru
mmf
mycophenol
mofetil
